👋Urologist here Good news for that waiting room: prostate cancer screening starts with a blood test 👆The finger is optional under current guidelines. If this cartoon is why you've been putting it off, don’t worry 😉 Talk to your doctor about screening for #ProstateCancer @Movember @AmerUrological @justindubinmd

🚨 93% active surveillance for low-risk #prostatecancer in the VA system 🚨 @JAMA_current 👥 73,042 pts w/ NCCN low or favorable intermediate risk PCa, VA system 2005 to 2024 📊 38,130 managed initially w/ surveillance or watchful waiting ✅ Low risk: AS use 27% to 93% ✅ Favorable intermediate: 14% to 61% ✅ GG1 w/ PSA 10 to 20: 27% to 88%. GG2 in <50% of cores: 11% to 55% ✅ For GG1 dx 2015 to 2024, nearly every VA facility sat between 60% and 100% ⚠️ For context: ~60% national AS rate for low risk in AQUA those same year ⚠️ Gaps remain: lower AS odds for Black (OR 0.95) and Hispanic (OR 0.85) pts and higher area deprivation, independent of risk 🎯 Bottom line: an integrated system w/ guideline monitoring, no financial reward for intervening, and nowhere to opinion-shop got AS to 93%. 👉The barrier to surveillance was never the evidence. It was the incentives. 🔗doi.org/10.1001/jama.2026.13… @dr_coops @AmerUrological @UroOnc @SUO_YUO @PCFne @UrologyTimes @renalandurology @urotoday @GabeCanales

👏Right on Matt!! Great day shining a light on important issues in #ProsateCancer care Incentives often drive practice over evidence! @PCF_Science @PCFnews

Medical school and residency are not just about learning medicine They are also critical periods for developing emotional intelligence (EQ) and strong teamwork skills. Can’t count how many times I’ve said this.

🚨 PARP-i in metastatic hormone-sensitive #ProstateCancer🚨 📜#TALAPRO3 out in @NEJM In HRR-altered mHSPC, adding talazoparib to enzalutamide + ADT: ✅ Reduced risk of progression/death by 52% (HR 0.48) 📈 3-year rPFS: 77% vs 56% ⏳ OS trend favors combination (HR 0.77), but immature. ⚠️ More anemia (Grade ≥3: 51%). 👉Potential new standard for a biomarker-selected population @neerajaiims @urotoday @renalandurology @UrologyTimes @UroOnc @SUO_YUO @PCFnews 🔗shorturl.at/2PBvi

🚨 PSA can be flat while #prostatecancer grows 🚨 @JCO_ASCO 👥 >2,500 pts, advanced PCa 📊 pooled ARCHES + PROSPER, enzalutamide 📊 radiographic progression vs PSA change ✅ ~1 in 4 had progression on imaging w/ stable or undetectable PSA ✅ those pts had worse survival ⚠️ post-hoc, ARSI-treated pts only 🎯 on potent AR inhibitors, PSA is necessary but not sufficient. scan f/u matters, esp the first 2 yrs. @PCFnews @PCF_Science @AarmstrongDuke